跳至主要内容
临床试验/EUCTR2015-001081-26-Outside-EU/EEA
EUCTR2015-001081-26-Outside-EU/EEA进行中(未招募)不适用

The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children with ADHD

Ortho-McNeil Janssen Scientific Affairs LLC0 个研究点目标入组 78 人开始时间: 2015年4月24日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
78

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • - ADHD diagnosis of all subtypes (except Not Otherwise Specified)
  • - Patients with total or subscale Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS-IV) scores > =90th percentile relative to the general population of children by age and gender
  • - Patients currently receiving ADHD medication must be inadequately managed on their current stimulant dose and meet this criteria at the screening visit
  • - Ability to read and understand English
  • - Ability to attend school regularly.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 78
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Estimated Full Scale IQ score of 80 or below
  • - Severe Learning Disability
  • - History of, or current, primary diagnosis of: severe anxiety disorder, conduct disorder, psychotic disorders, pervasive developmental disorder, eating disorder, obsessive-compulsive disorder, sleep disorder, major depressive disorder, bipolar disorder, substance use disorder, chronic tic disorder, personal or family history of Tourette's syndrome
  • - Weight < 3rd percentile for age
  • - History of hospitalization for treatment of a mood, anxiety, or psychotic disorder
  • - History of failed response to methylphenidate.

研究者

相似试验

招募中
1 期
An Exploratory Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ZE63-0302 in Healthy VolunteersAcute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemia
ACTRN12624000180516Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)88
已完成
3 期
A clinical trial to study the effects of the drug Asacol 4,8g/day (800 mg tables) in patients with active Ulceratice Colitis
CTRI/2010/091/000387Tillotts Pharma AG280
进行中(未招募)
1 期
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBC
EUCTR2020-002686-33-FRSeattle Genetics, Inc.400
进行中(未招募)
1 期
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCdiffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851
EUCTR2020-002686-33-PLSeagen Inc.400
撤回
3 期
A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)DLBCL
NL-OMON52039Seagen Inc.4